Literature DB >> 26797241

The Parity Paradigm: Can Legislation Help Reduce the Cost Burden of Oral Anticancer Medications?

Sheetal M Kircher1, Caitlin R Meeker2, Halla Nimeiri3, Daniel M Geynisman2, S Yousuf Zafar4, Veena Shankaran5, Jonas de Souza6, Yu-Ning Wong2.   

Abstract

Over the last decade, there has been increased development and use of oral anticancer medications, which sometimes leads to high cost sharing for patients. Drug parity laws require insurance plans to cover oral anticancer medications with the same cost sharing as intravenous/injected chemotherapy or have a capped limit on out-of-pocket costs. There are currently 36 enacted state laws (plus the District of Columbia) addressing drug parity, but no federal laws. In this policy perspective piece, we discuss the history, opportunities, and limitations of drug parity laws in oncology. We also discuss the implications of provisions of the Affordable Care Act and other proposed policy reforms on financing oral chemotherapy.
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  drug costs; neoplasms

Mesh:

Substances:

Year:  2015        PMID: 26797241     DOI: 10.1016/j.jval.2015.10.005

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  12 in total

1.  The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer.

Authors:  Alexander L Chin; Jason P Bentley; Erqi L Pollom
Journal:  Cancer       Date:  2018-12-19       Impact factor: 6.860

2.  Use of Charity Financial Assistance for Novel Oral Anticancer Agents.

Authors:  Adam J Olszewski; Andrew R Zullo; Christopher R Nering; Justin P Huynh
Journal:  J Oncol Pract       Date:  2018-02-13       Impact factor: 3.840

Review 3.  Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.

Authors:  Jeffrey Betcher; Elizabeth Dow; Nandita Khera
Journal:  Curr Hematol Malig Rep       Date:  2016-08       Impact factor: 3.952

4.  Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.

Authors:  Ya-Chen Tina Shih; Ying Xu; Lei Liu; Fabrice Smieliauskas
Journal:  J Clin Oncol       Date:  2017-05-04       Impact factor: 44.544

Review 5.  Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty.

Authors:  Talal Hilal; Jeffrey A Betcher; Jose F Leis
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

6.  Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.

Authors:  Ashley M Perry; Andrew M Brunner; Tao Zou; Kristin L McGregor; Philip C Amrein; Gabriela S Hobbs; Karen K Ballen; Donna S Neuberg; Amir T Fathi
Journal:  Cancer       Date:  2017-05-02       Impact factor: 6.860

7.  Oral Oncology Parity Laws, Medication Use, and Out-of-Pocket Spending for Patients With Blood Cancers.

Authors:  Stacie B Dusetzina; Haiden A Huskamp; Shelley A Jazowski; Aaron N Winn; William A Wood; Adam Olszewski; Ethan Basch; Nancy L Keating
Journal:  J Natl Cancer Inst       Date:  2020-10-01       Impact factor: 13.506

8.  Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.

Authors:  Adam J Olszewski; Stacie B Dusetzina; Charles B Eaton; Amy J Davidoff; Amal N Trivedi
Journal:  J Clin Oncol       Date:  2017-05-25       Impact factor: 50.717

9.  Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.

Authors:  Adam J Olszewski; Stacie B Dusetzina; Amal N Trivedi; Amy J Davidoff
Journal:  J Clin Oncol       Date:  2018-08-16       Impact factor: 50.717

Review 10.  Strategies for reducing out of pocket payments in the health system: a scoping review.

Authors:  Faride Sadat Jalali; Parisa Bikineh; Sajad Delavari
Journal:  Cost Eff Resour Alloc       Date:  2021-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.